Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2021, Allogene Therapeutics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 12, 2021, the record date for the Annual Meeting, 141,485,913 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

Proposal 1. Election of Directors

The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:


                 Votes For       Votes Withheld        Broker Non-Votes
John DeYoung    111,401,689         8,576,418             8,764,205
Franz Humer     111,404,617         8,573,490             8,764,205
Joshua Kazam    94,429,527         25,548,580             8,764,205

Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting. The final voting results are as follows:



    Votes For        Votes Against       Abstentions        Broker Non-Votes
    97,963,279        22,027,420            14,408             8,764,205

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The final voting results are as follows:

Votes For Votes Against Abstentions Broker Non-Votes


    128,714,246          17,530              10,536                 -


Item 9.01  Financial Statements and Exhibits.
(d)
Exhibit
Number                                   Description
104          The cover page of this report has been formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses